1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Yuyu Pharma, Inc.

Yuyu Pharma, Inc.

000225.KS
Yuyu Pharma, Inc.KR flagKorea Exchange
3,600.00
KRW
+225.00
- -
59.49BMarket Cap
Yuyu Pharma, Inc.
000225.KS
(Korea Exchange)

Recent

price

3,600.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
52,027
58,799
61,985
61,994
62,816
69,743
71,579
62,852
83,096
90,878
98,120
115,655
138,881
137,210
133,147
140,885
143,520
Sales/Revenue/Turnover
2.49
3.57
6
2.83
2.18
2.31
5.22
5.68
6.41
8.89
6.39
1.04
-0.43
0.27
9.45
7.82
7.95
Operating Margin (%)
2,246
1,695
1,549
1,633
1,510
1,542
1,601
1,461
2,127
3,121
3,899
4,503
5,027
5,607
5,666
5,608
5,622
Depreciation Expense
1,117
1,907
2,979
1,877
-7,467
-253
5,886
4,541
4,020
4,722
1,284
-2,214
-5,988
-7,181
8,720
8,154
9,052
Net Income, GAAP
- -
- -
16.74
26.53
- -
- -
5.99
10.9
7.23
15.71
34.99
- -
- -
- -
- -
3.86
5.35
Effective Tax Rate (%)
2.15
3.24
4.81
3.03
-11.89
-0.36
8.22
7.23
4.84
5.2
1.31
-1.91
-4.31
-5.23
6.55
5.79
6.31
Profit Margin (%)
17,660
16,822
20,201
28,344
22,673
19,809
25,453
27,987
41,082
22,558
46,068
68,873
32,042
51,621
37,468
37,967
38,291
Working Capital
- -
- -
200
3,956
- -
- -
- -
1,349
18,181
3,070
14,972
28,739
1,851
14,021
402
257
428
LT Debt
70,642
67,229
69,501
72,276
71,489
73,731
78,291
82,834
86,872
90,545
117,036
128,685
123,374
120,356
135,063
140,544
142,557
Total Equity
- -
- -
4.48
1.79
- -
- -
3.94
3.34
4.63
5.91
3.26
- -
- -
- -
- -
6.28
6.37
Return on Invested Capital (%)
- -
- -
6.72
4
- -
- -
10.82
8.5
6.7
7.02
1.72
- -
- -
- -
- -
10.58
11.77
Return on Capital (%)
2.51
4.42
7.03
4.27
-18.67
-0.73
16.25
11.37
9.43
10.45
2.65
-4.24
-11.61
-16.55
21.48
17.44
18.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
28,677
27,666
25,787
LT Borrowings
33
- -
- -
LT Finance Leases
244
257
428
Preferred Equity and Hybrid Capital
2,592
2,592
2,592
Shares Outstanding
16
16
16
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
96,665
96,914
94,788
Cash, Cash Equivalents & STI
28,669
32,705
29,887
Accounts Receivable, Net
20,826
18,553
20,060
Inventories
44,317
42,221
39,486
Total Current Liabilities
54,758
58,948
56,497
Payables & Accruals
- -
- -
- -
ST Debt
28,677
27,666
25,787
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7%
3.93%
4.06%
Free Cash Flow
-122.18%
-51.1%
-57.93%
Net Income, GAAP
-282.9%
-62%
-6.49%
Sales/Revenue/Turnover
7.96%
7.92%
5.81%
Total Cash Common Dividend
- -
- -
-3.63%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,405
33,177
33,600
32,966
133,147
2025
32,907
35,846
37,792
34,339
140,885
2026
35,542
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Zeria Pharmaceutical Co., Ltd. (4559.T)
Dermapharm Holding SE (DMPHF)
AusCann Group Holdings Ltd (AC8.AX)
Jacobson Pharma Corporation Limited (2633.HK)
Nascent Pharma Holdings, Inc. (NASC)
Chalice Brands Ltd. (CHAL.CN)
Business
Yuyu Pharma, Inc. is a South Korean pharmaceutical company primarily engaged in the development, manufacturing, and distribution of prescription drugs and over-the-counter pharmaceutical products. Its product portfolio spans various categories including cardiovascular agents, central nervous system drugs, anti-diabetics, gastrointestinal medicines, and respiratory therapeutics. The company also offers active pharmaceutical ingredients (APIs) and engages in contract manufacturing services. Yuyu Pharma operates extensively in South Korea and exports to international markets, focusing on providing innovative and quality healthcare solutions. Founded in 1941 and headquartered in Seoul, South Korea, Yuyu Pharma pursues strategic growth through recent product launches and business expansion within the pharmaceutical sector. Over the last one to two years, the company has strengthened its market presence by enhancing its research and development capabilities and pursuing strategic collaborations to expand its therapeutic offerings. The company continues to focus on innovation in drug development and aims to broaden its footprint in both domestic and global pharmaceutical markets. Yuyu Pharma belongs to the pharmaceutical industry and primarily serves hospitals, clinics, and retail pharmacies as its target customers. Its offerings include both branded and generic medications catering to chronic and acute conditions. The company also maintains a focus on regulatory compliance and quality assurance in its manufacturing processes. Yuyu Pharma, Inc. is recognized for its comprehensive pharmaceutical product lines and commitment to improving patient health outcomes through advanced medicinal products.